– 26 scientific abstracts, including two oral presentations, demonstrate UCB s ongoing commitment to advancing research for people living with epilepsies
– Data include an open-label extension study describing the long-term safety of FINTEPLA®? (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2]
– Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic cha
Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines.
Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company s newly established Cambridge location, where he will establish a group of world-class biomedical talent as the company advances its work translating AI-driven drug discovery
MedHub-AI (http://www.medhub-ai.com/), pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical accuracy compared to conventional 3D FFR methodologies.
BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic science to clinical trials.
BIAL will be presenting the ACTIVATE study, a Phase II trial evaluating the effic
ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.
Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging—in Sweden and Denmark.
The introduction of Isoprotrace® into these Nordic markets marks a significant step forward in expanding access to precision diagnostic tools for prostate cancer. Isoprotrace® is a ready-to-use, multi-dose kit designed for the efficient preparation of Gallium-68 Gozetot
A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant under the EIC Transition Programme of Horizon Europe.
The funding will drive the consortium s collaborative efforts to develop NeutroFlow—a novel, point-of-care diagnostic test designed to predict patient response to immune checkpoint inhibitors (ICIs) acros
Healthcare Holding Schweiz AG, a leading provider of services and distributor of medical technology in Switzerland, has expanded its portfolio by acquiring CDP Swiss AG and CDP Austria GmbH. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH.
Healthcare Holding Schweiz AG has successfully closed the acquisition of CDP Swiss AG, based in Affoltern, and its subsidiary, CDP Austria GmbH, located in Lustenau. CDP Swiss AG is an ISO-certified, multi-brand company renowned for offering
Briya (http://www.briya.com/), a leading healthcare data retrieval network, is proud to announce a strategic partnership with Casa Sollievo della Sofferenza, one of Italy s premier hospitals renowned for its advanced medical care and research initiatives. This collaboration marks a significant step in addressing a long-standing challenge in European medical research: the difficulty of accessing high-quality, real-world data (RWD) across the region.
A groundbreaking dermatological alliance will bring innovative dermatological treatment to the 27 million residents of the Nordic Region, offering rapid and efficient treatment for the most common skin cancer and various skin conditions – often completed in under 90 seconds.
TOOsonix A/S, a leader in high-intensity focused ultrasound technology for dermatology, has partnered with MikronMed AB, a top distributor of medical equipment in the Nordic region. The collaboration will bring TOOsonix inn
